| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXEL | Common Stock | Options Exercise | $3,051,250 | +125,000 | +17% | $24.41 | 846,680 | 09 Aug 2024 | Direct | F1 |
| transaction | EXEL | Common Stock | Sale | $3,398,750 | -125,000 | -15% | $27.19 | 721,680 | 09 Aug 2024 | Direct | F1, F2 |
| holding | EXEL | Common Stock | 2,723 | 09 Aug 2024 | By 401(k) | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXEL | Option (right to buy) | Options Exercise | $0 | -125,000 | -100% | $0.000000* | 0 | 09 Aug 2024 | Common Stock | 125,000 | $24.41 | Direct | F4 |
| Id | Content |
|---|---|
| F1 | Includes 272,874 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. |
| F2 | Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.08 to $27.35. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. |
| F3 | Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of August 8, 2024. |
| F4 | The option, representing the right to purchase a total of 125,000 shares of Exelixis, Inc. common stock became fully exercisable on October 3, 2021. |